Generics - Generics, Hikma Pharmaceuticals

Filter

Popular Filters

Hikma to take over Boehringer’s Ben Venue manufacturing site

24-07-2014

Jordan-based drugmaker Hikma Pharmaceuticals says it has agreed with Ben Venue Laboratories, part of…

Ben Venue LabsBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsProductionUSA

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

28-05-2014

Jordon-based drugmaker Hikma Pharmaceuticals has signed an asset purchase agreement with Ben Venue Laboratories,…

Bedford LaboratoriesBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsUSA

Hikma’s US facility back in compliance

Hikma’s US facility back in compliance

02-04-2014

Hikma Pharmaceuticals, Jordan's largest pharmaceutical company, has received a close-out letter from…

GenericsHikma PharmaceuticalsJordanPharmaceuticalRegulation

Hikma delivers group revenue growth of 23% and EPS up 111% for 2013

Hikma delivers group revenue growth of 23% and EPS up 111% for 2013

12-03-2014

Jordon-headquartered Hikma Pharmaceuticals today reported its preliminary results for the year ended…

FinancialGenericsHikma Pharmaceuticals

Hikma in $40 million deal to enhance delivery of generic injectables

20-11-2013

USA-based Unilife Corp has signed a long-term commercial supply contract with Jordan-headquartered Hikma…

GenericsHikma PharmaceuticalsLicensingMarkets & MarketingUnilife Corp

Hikma sets up JV for entering Ethiopian pharma market

Hikma sets up JV for entering Ethiopian pharma market

18-09-2013

Jordon-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) says that it has signed a 50:50 joint…

GenericsHikma PharmaceuticalsMarkets & MarketingMergers & AcquisitionsMIDROC PharmaceuticalsRest of the World

Hikma first half EPS beats expectations; raises guidance

21-08-2013

Jordan-headquartered drugmaker Hikma Pharmaceuticals (HIK: LSE) this morning (August 21) reported financial…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Jordon's Hikma upgrades 2013 guidance

08-07-2013

Jordon-based Hikma Pharmaceuticals (LSE: HIK) has issued an upgraded guidance for 2013, saying that its…

FinancialGenericsHikma Pharmaceuticals

Hikma to retain its global Injectables business

17-04-2013

Further to its announcement last month that it was undertaking a review of the strategic options for…

FinancialGenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceutical

Hikma delivers revenue growth of 21% and EPS up 24% for 2012

13-03-2013

Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) has reported preliminary results for 2012, showing…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma leaps as it confirms unsolicited interest in Injectables business

04-03-2013

Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) saw its shares jump 8.1% to£9.365 on Friday,…

FinancialGenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceutical

Hikma to buy Egyptian pharma company for around $20 million

10-01-2013

Fast-growing Jordan-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) says it has agreed to acquire…

Egyptian Company for Pharmaceuticals & ChemicGenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceuticalRest of the World

Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region

22-10-2012

Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the…

GenericsGP PharmHikma PharmaceuticalsLicensingLutrateOncologyRest of the World

Solid first-half 2012 results from Jordan's Hikma

16-08-2012

Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) has reported its interim results for…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma may invest $100 million in Ukrainian pharma market

15-05-2012

Hikma Pharmaceuticals (LSE: HIK), Jordan's largest pharmaceutical company which is listed on the London…

EuropeFinancialGenericsHikma Pharmaceuticals

Hikma earnings down despite 25.6% revenue growth

14-03-2012

Fast-growing Jordan headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) delivered what it called…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma adds to stake in Promopharm; gets US appro for argatroban

22-01-2012

Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has increased its stake…

ArgatrobanCardio-vascularGenericsHikma PharmaceuticalsMergers & AcquisitionsNorth AmericaPharmaceuticalPromopharmRegulationRest of the World

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region

24-11-2011

Canada’s AEterna Zentaris (TSX: AEZ) has signed an exclusive commercialization and licensing agreement…

AEterna ZentarisGenericsHikma PharmaceuticalsLicensingOncologyperifosinePharmaceuticalRest of the World

Hikma enters Moroccan market via $111 million controlling stake in Promopharm

05-10-2011

Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has acquired 63.9% of Promopharm (Societe…

GenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceuticalPromopharmRest of the World

Back to top